Company Analysis

Definium Therapeutics, Inc. (DFTX)

Nasdaq: DFTX · Medicinal Chemicals & Botanical Products · New York, NY · filing with the SEC since 2020
Grade5.3
◀ Past 4.4● Present 5.2▶ Future 6.5
6 est.

Who runs Definium Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Barrow Robert
Chief Executive Officer. First filing Jan 2022, latest Sep 29, 2026, 30 filings in all.
Officers reporting now
5
of 11 people with a filing in the last fifteen months
Directors reporting now
6
18 people on the record since 2022
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Barrow RobertChief Executive OfficerJan 2022Sep 29, 20265 · $4.0M
Roberts BrandiChief Financial OfficerJun 2025Sep 29, 20262 · $300,000
Karlin DanChief Medical OfficerJan 2022Sep 29, 20264 · $1.1M
Sullivan MarkChief Legal OfficerApr 2023Sep 29, 20264 · $1.4M
Wiley Matthew T.Chief Commercial OfficerMar 2025Sep 29, 20262 · $200,000
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Krebs AndreasdirectorJan 2022Sep 18, 2026none
Vallone Carol AdirectorJan 2022Sep 18, 2026none
Adsett RogerdirectorJan 2026Jun 15, 2026none
Bruhn Suzanne LouisedirectorAug 2022Jun 15, 2026none
Crystal RogerdirectorAug 2022Jun 15, 2026none
Gryska David WdirectorJun 2023Jun 15, 2026none
Earlier names on the record7, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton DFTX · research, not advice